What Суматриптан-Тева Treats: Main Uses and Benefits

This medication is commonly used as an acute, abortive treatment specifically for episodes of diagnosed migraine headaches and, in some forms, cluster headaches. It is applied during the attack with the goal of assisting in halting the progression of the episode, and may offer symptomatic relief in clinical settings marked by the sudden onset of intense, debilitating head pain. The medication is relevant for managing symptom clusters that often accompany these conditions.

The primary use is to assist with managing symptoms during acute episodes of headache syndromes, particularly when symptoms include severe throbbing pain, sensitivity to light (photophobia), sensitivity to sound (phonophobia), and nausea or vomiting. By assisting in easing these challenging symptoms of moderate-to-severe attacks, the treatment offers symptomatic relief that helps patients cope more steadily with difficult episodes. This approach may assist with maintaining functional stability and routine activities.

Quick Fact: Relief for Associated Distress
Supports easing the overall burden of symptoms, including light sensitivity and nausea, beyond addressing the core pain.

Regulatory References

1. NIH MedlinePlus overview on Sumatriptan

This medication is officially indicated for use by Adults with a clear diagnosis of migraine. Certain patient populations and medical conditions strictly prohibit its use, while others require special caution.

Populations for whom use is Contraindicated

Use of Суматриптан-Тева is prohibited for patients with:

• Ischemic Cardiovascular Disease (e.g., history of heart attack, angina, or Prinzmetal's angina) or other significant underlying heart conditions.
• History of Cerebrovascular Events (e.g., stroke or transient ischemic attack, TIA).
• Uncontrolled or Severe Hypertension.
• Severe Hepatic Impairment (severe liver disease).
• Concomitant use of Monoamine Oxidase Inhibitors (MAOIs), ergotamine derivatives, or other triptans within 24 hours (or two weeks for MAOIs).
• Hemiplegic, Basilar, or Ophthalmoplegic Migraine types.

Restricted or Not Recommended Use

Population/Condition	Eligibility Status (Regulatory)
Children & Adolescents (under 18)	Not recommended (efficacy not demonstrated)
Elderly (over 65 years)	Not recommended (limited experience)
Pregnancy	Conditional use (only if benefit outweighs risk)
Lactation	Restricted (avoid breast-feeding for 12 hours after dose)
Cardiovascular Risk Factors	Requires prior cardiovascular evaluation
Mild Controlled Hypertension	Use with caution
Seizure History	Use with caution

All use should be based on a clear diagnosis of migraine headache by a healthcare professional.

Official Interaction Restrictions

The regulatory profile for Sumatriptan Succinate defines specific interaction patterns with other medicines and products, primarily involving pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms, which necessitate mandatory restrictions and contraindications.

Strict Contraindicated Combinations

• MAO-A Inhibitors: Co-administration is strictly prohibited due to inhibition of the metabolic enzyme MAO-A, which results in reduced drug clearance and a documented two-fold increase in Sumatriptan's systemic exposure. A mandatory 14-day (two-week) separation period is required following the discontinuation of an MAO-A inhibitor.
• Ergot-Containing Medications and Other Triptans: Use is strictly contraindicated because these substances carry a high pharmacodynamic risk for additive vasoconstrictive effects, potentially leading to prolonged vasospastic reactions.

Timing-Based Administration Rules

To mitigate the risk of cumulative vasoconstriction, Sumatriptan must be separated from the administration of any ergot-containing medication or other 5- HT1 receptor agonist by an interval of 24 hours.

Risk of Serotonin Syndrome

Official regulatory warnings note the potential for Serotonin Syndrome when Sumatriptan is co-administered with other serotonergic agents, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). The herbal product St John's Wort is also documented as potentially increasing this serotonergic risk and should be avoided.

Population-Specific Caution

Sumatriptan is contraindicated in patients with severe hepatic impairment. This restriction is based on the impairment of drug clearance in this population, leading to the risk of high systemic drug exposure.

How Суматриптан-Тева Works

The action of Суматриптан-Тева is defined by its selective agonism on two subtypes of serotonin receptors, 5-HT1B and 5-HT1D, situated within the cranial neurovascular system. This molecular interaction produces complementary physiological effects that interrupt the neurogenic cascade.

Targeted Constriction of Cranial Blood Vessels

The molecule selectively activates 5-HT1B receptors on the smooth muscle of certain intracranial arteries. This action initiates a cascade of smooth muscle contraction, resulting in the induction of vasoconstriction, which reverses excessive vasodilatation. This physiological adjustment results in functional constriction of cranial blood vessels.

Inhibition of Neurogenic Inflammation Signaling

By activating 5-HT1D receptors located presynaptically on trigeminal nerve endings, the drug achieves inhibition of neuropeptide release. This mechanism suppresses the release of vasoactive mediators, specifically Calcitonin Gene-Related Peptide (CGRP), which suppresses localized neurogenic inflammation. This targeted modulation affects the peripheral nociceptive pathway.

Constraint on Mechanism of Action

The primary mechanism is focused on acute neurovascular events involving receptor-mediated vasoconstriction and neuropeptide inhibition. The mechanism is functionally constrained to those processes and does not apply to the initial neurological events (e.g., aura), nor does it affect pain pathways unrelated to the trigeminal-vascular system activation.

Official Administration and Dosing Guidelines

Суматриптан-Тева (Sumatriptan Succinate) is intended solely for the acute, abortive treatment of an attack that has already begun, and must not be used for prophylactic (preventive) treatment. The drug is available for administration via the oral (tablet), subcutaneous (SC injection), and intranasal (spray/powder) routes, allowing for various patient needs.

Standard Dosing and Frequency

Route	Single Dose	Minimum Interval Before Repeat Dose	Maximum Dose in 24 Hours
Oral Tablet	25 mg, 50 mg (common start), or 100 mg	at least 2 hours	200 mg
SC Injection	6 mg (standard for cluster headache)	at least 1 hour	12 mg (two 6 mg doses)

Specific Use Instructions

• Timing of Intake: The medication should be taken as early as possible after the onset of the acute symptoms. If the first dose provides no relief, a second dose should not be taken for the same attack, though it may be used for subsequent attacks.
• Tablet Administration: Oral tablets must be swallowed whole with water and should not be crushed or chewed.
• Population Adjustments: For adult patients with mild to moderate hepatic impairment, the maximum single oral dose should not exceed 50 mg. The safety of treating an average of more than 4 headaches in a 30-day period has not been established.

Research Evidence / Overview of studies for Суматриптан-Тева

---

Evidence for Use in Acute Migraine Headaches

This section summarizes the large body of research, primarily consisting of Randomized Controlled Trials (RCTs) and Systematic Reviews, that have examined the acute administration of the medicine for migraine episodes. It will outline the specific endpoints that these studies were designed to measure, which included the measured pain status of freedom, the outcome of pain reduction, and the absence of associated symptoms like nausea and sensitivity to light or sound.

Research has focused on individuals experiencing acute migraine episodes, whether the attacks involve visual changes (with aura) or not (without aura). The studies explored the effects observed when the medicine was applied during periods of heightened symptom activity. Across the clinical trials, research monitored outcomes related to the participants' physical discomfort and episodic changes, primarily measuring the proportion of individuals who reported changes in symptom intensity over a short period. Studies described the patterns observed in measurements of headache severity and the complete absence of pain at set time intervals, usually one or two hours after administration. Evidence contributes to understanding symptom patterns by looking at how symptoms evolved in the observed populations.

The research also applied in studies examining patient-reported experiences related to common associated symptoms. This included measuring changes in outcomes related to functional imbalance, specifically the absence of nausea and sensitivity to environmental factors like light (photophobia) and sound (phonophobia). Systematic reviews describing the overall body of evidence reported patterns in the sustained measurements of pain freedom tracked up to 24 hours post-dose without the need for rescue medication.

---

Evidence for Use in Acute Cluster Headaches

This portion describes the research that supports the use of the medicine for cluster headache attacks, focusing on the studies that examined the rapid-onset subcutaneous formulation. The summary will detail the specific outcomes measured in these trials, particularly the measurement of pain reduction at very short time intervals post-administration.

The evidence for cluster headaches is mainly derived from focused Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and applied in research contexts involving rapidly fluctuating or unstable symptoms typical of these conditions. Studies monitored outcomes describing episodic or acute changes in pain, with measurements taken at very quick time intervals, typically 15 and 30 minutes following the subcutaneous administration. Findings describe patterns observed in the studies related to the proportion of individuals reaching a measured endpoint of pain reduction shortly after treatment.

The reported outcomes are largely confined to the use of the subcutaneous (injection) dosage form, as this form was the primary focus of the foundational cluster headache trials. Research highlights changes measured during the study period, primarily documenting the immediate outcome following a limited number of attacks.

---

Long-Term Research and Consistency of Response

This section outlines what the clinical research reported regarding outcomes tracked beyond the initial two-hour post-dose period. It will summarize available data on the durability of the response (e.g., 24-hour sustained relief) and the consistency of outcomes across multiple treated attacks in longer observational periods.

While the primary efficacy endpoints in the clinical trials were short-term, research did examine how symptoms evolved in the observed populations over extended time intervals. This involved monitoring the proportion of individuals whose pain status remained classified as the measured endpoint of pain freedom without rescue medication over the 24-hour period following administration of the treatment. Beyond the single-attack outcomes, some studies explored the consistency of an individual's outcomes when treating successive acute attacks over a period of months.

However, existing studies provide limited insight into long-term outcomes for patients who treat a high frequency of attacks. Research exploring continuous or very frequent use is not fully characterized, and data for long-term outcomes are not fully established.

---

Evidence in Special Populations and Subgroups

This area summarizes the extent of research available for specific patient groups, including studies that have evaluated the medicine in adolescents and the noted limitations regarding established data for the geriatric or very young pediatric populations. It will also touch upon research pertaining to subgroups of patients with particular patterns of outcome or non-response.

The majority of the evidence comes from studies focused on Adults (aged 18 to 65). Some separate trials were conducted, and research was examined for the Adolescent population (12–17 years) with migraine, indicating that data show patterns related to outcomes in this specific group.

Conversely, data for certain groups remain insufficient. Regulatory documentation indicates that evidence is limited for the pediatric population (children under 12 years of age). Similarly, evidence quality may vary across studies, and data for the geriatric population (older adults) is noted as limited or not fully established. Furthermore, trials exploring temporary physiological imbalance have largely excluded individuals with certain complex or severe pre-existing medical conditions.

---

Understanding Evidence Gaps and Areas of Uncertainty

This final section synthesizes the main evidence limitations and areas where data are less extensive, as documented in authoritative scientific reviews and regulatory documents. It clarifies known research gaps, such as the need for more established data in certain populations or the inconsistency of outcome reported for a subset of individuals.

Research highlights what is known and what is still uncertain about the treatment. One key limitation is that study results reflect the specific conditions under which they were conducted, and evidence indicates that a subset of patients has been observed to have an inconsistent or incomplete outcome measured across different treated episodes. This finding describes a pattern observed in the studies, but research does not determine whether an individual will respond similarly.

For cluster headache, the overall volume of clinical trials and the sample sizes were noted in systematic reviews as being modest compared to the migraine research. Therefore, evidence quality may vary across studies. For both conditions, there is limited information for long-term outcomes, as follow-up durations were primarily focused on the acute and short-term response periods.

Common questions about Суматриптан-Тева (FAQ)

Q: How long after taking the oral tablet does it take for the pain to start going away?

Regulatory reviews of clinical trials indicate that the efficacy of the oral tablet is assessed at specific, short time points. In studies, the primary measurement points for assessing the proportion of patients who achieve pain relief or pain freedom are typically one and two hours after administration.

Q: Can I use the subcutaneous injection for a regular migraine, or is it only for cluster headaches?

According to the official product information, the subcutaneous injection is indicated for the acute treatment of both migraine headaches and cluster headache episodes. The injection is recognized clinically for its ability to deliver the medication quickly.

Q: What are the most common side effects of the drug?

Official regulatory documents list several common side effects. Commonly reported side effects may include sensations such as tingling, dizziness, warm or hot feelings, and brief feelings of tightness or pressure in the chest, throat, or neck. If the injection is used, reactions at the injection site are also common.

Q: What happens if I take Sumatriptan with an SSRI or St. John’s Wort?

Official warnings note the potential for Serotonin Syndrome when these medicines or supplements are combined with Sumatriptan. Serotonin Syndrome is a serious condition, and symptoms may involve changes in mental status, unstable blood pressure, and a fast heart rate.

Q: What should I do if I accidentally overdose on Sumatriptan?

In the event of a suspected overdose, regulatory information emphasizes that emergency medical attention should be sought immediately. Symptoms of an overdose may include convulsions and cardiovascular issues. Medical care following an overdose often involves supportive measures and monitoring for at least 12 hours, according to official guidelines.

Q: How do I use the nasal spray device?

Official patient instructions provide a detailed procedure for administering the nasal spray device. These instructions describe the necessary steps, such as preparing the device and the proper technique for administration, and are included with the product.

Q: Is it safe to use Sumatriptan while I am breastfeeding?

Regulatory guidance indicates that the active ingredient is found in human breast milk. Therefore, the official guidance suggests avoiding breastfeeding for 12 hours following administration to minimize exposure to the infant.

Q: Is Sumatriptan a controlled substance?

According to official drug regulatory status in the United States, Sumatriptan is not classified as a controlled substance under the Controlled Substances Act (DEA Schedule I-V).

How to Store and Dispose of Sumatriptan

Sumatriptan tablets and injections must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from excess heat, moisture, and freezing; the container should be kept tightly closed and in its original packaging.

All forms of this medication must be stored out of the sight and reach of children to prevent accidental ingestion.

For disposal, unused or expired medication should be returned through a medicine take-back program if available. If a take-back program is not available, the medication should be mixed with an undesirable substance and placed in a sealed bag before being disposed of in the household trash. Used injection needles and syringes must be placed immediately into an FDA-cleared sharps disposal container.